The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene.

Another TIGIT trial failure has been abandoned, casting a shadow once again over the target as a cancer immunotherapy strategy. The latest setback is in a phase 3 trial of MSD's anti-TIGIT ...

TIGIT inhibitors have long been in a difficult race toward the finish line on the non-small cell lung cancer (NSCLC) track. At the European Society for Medical Oncology (ESMO) Congress 2024, GSK and ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light for anti-TIGIT therapies after a string of failures. GSK and iTeos ...

TIGIT inhibitors have long been in a difficult race toward the finish line on the non-small cell lung cancer (NSCLC) track. At the European Society for Medical Oncology (ESMO) Congress 2024, GSK ...

Protein design (or protein engineering) is a technique by which proteins with enhanced or novel functional properties are created. Proteins can be engineered by rational design, which typically ...

M K Proteins Ltd., incorporated in the year 2012, is a Small Cap company (having a market cap of Rs 350.22 Crore) operating in Agro Processing sector. M K Proteins Ltd. key Products/Revenue Segments ...

A peptide is a short chain of two or more amino acids linked by a chemical bond called a peptide bond. When organized into complex structures (typically consisting of 50 or more amino acids), peptides ...